Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (27 quarters reported)
$159M in Q4 2019 → $624M now. Hover for any quarter.
As reported for the quarter ended June 30, 2026. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| Dianthus Therapeutics Inc | 32.8% | Trimmed 50% | 2,104,184 | $205M |
| Cg Oncology Inc | 15.9% | Added 8.5% | 1,398,948 | $99.4M |
| Oruka Therapeutics Inc | 11.6% | Trimmed 50% | 760,424 | $72.4M |
| Jade Biosciences Inc | 6.1% | Trimmed 39% | 1,700,708 | $37.8M |
| Enliven Therapeutics Inc | 4.5% | Trimmed 31% | 550,000 | $27.9M |
| Perspective Therapeutics Inc | 3.4% | Trimmed 48% | 6,299,999 | $21.5M |
| Aktis Oncology Inc | 2.5% | Trimmed 48% | 484,200 | $15.6M |
| PT Palvella Therapeutics Inc Ne | 1.7% | Trimmed 50% | 70,000 | $10.7M |
| MM Mobia Med Inc | 1.7% | New | 798,282 | $10.7M |
| Repligen Corp | 1.7% | Trimmed 50% | 77,800 | $10.6M |
| Immunic Inc | 1.6% | New | 669,941 | $10.3M |
| SH Senseonics Hldgs Inc | 1.5% | New | 1,600,000 | $9.09M |
| Karyopharm Therapeutics Inc | 1.4% | Trimmed 0.3% | 924,487 | $9.03M |
| TP Teva Pharmaceutical Inds Ltd | 1.1% | Trimmed 69% | 200,000 | $6.78M |
| Dexcom Inc | 1.1% | Trimmed 47% | 100,000 | $6.74M |
| Tempus Ai Inc | 1.0% | Added 17% | 105,000 | $6.08M |
| Medtronic PLC | 0.9% | Trimmed 65% | 70,000 | $5.48M |
| Vir Biotechnology Inc | 0.8% | Trimmed 67% | 519,300 | $5.29M |
| Structure Therapeutics Inc | 0.8% | Added 26% | 98,000 | $5.26M |
| Encompass Health Corp | 0.7% | Trimmed 50% | 42,000 | $4.25M |
| Tenax Therapeutics Inc | 0.6% | Trimmed 45% | 265,934 | $3.87M |
| Nuvectis Pharma Inc | 0.6% | New | 200,000 | $3.68M |
| Insulet Corp | 0.6% | Added 140% | 24,000 | $3.65M |
| Boston Scientific Corp | 0.5% | Trimmed 33% | 80,000 | $3.41M |
| Satellos Bioscience Inc | 0.5% | Trimmed 50% | 387,769 | $3.01M |
| Alamar Biosciences Inc | 0.5% | New | 110,000 | $2.98M |
| Context Therapeutics Inc | 0.4% | Trimmed 50% | 4,998,267 | $2.77M |
| Gilead Sciences Inc | 0.4% | Trimmed 50% | 20,000 | $2.53M |
| CR Charles Riv Labs Intl Inc | 0.4% | Unchanged | 10,000 | $2.27M |
| Phathom Pharmaceuticals Inc | 0.3% | Trimmed 60% | 200,000 | $2.17M |
| AP Avalyn Pharmaceuticals Inc | 0.3% | New | 60,000 | $1.98M |
| Kailera Therapeutics Inc | 0.3% | New | 80,000 | $1.76M |
| Genmab A/s | 0.2% | Trimmed 50% | 50,000 | $1.37M |
| Intellia Therapeutics Inc | 0.2% | Trimmed 50% | 75,000 | $1.27M |
| Corvus Pharmaceuticals Inc | 0.2% | Trimmed 65% | 80,000 | $1.2M |
| Oddity Tech Ltd | 0.2% | Trimmed 50% | 70,000 | $1.06M |
| Scynexis Inc | 0.2% | New | 260,206 | $1.06M |
| Evommune Inc | 0.2% | New | 75,000 | $997K |
| Abbott Laboratories | 0.1% | Unchanged | 10,000 | $907K |
| Bridgebio Pharma Inc | 0.1% | Unchanged | 10,000 | $745K |
| Peloton Interactive Inc | 0.1% | Trimmed 75% | 100,000 | $591K |
| Legend Biotech Corp | 0.1% | Unchanged | 15,000 | $433K |
| BO Bridgebio Oncology Therapeut | 0.1% | Trimmed 50% | 43,853 | $334K |
| Savara Inc | 0.0% | Unchanged | 50,000 | $308K |
| Trevi Therapeutics Inc | 0.0% | Trimmed 50% | 6,660 | $124K |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 8 quarters.
quarter ended June 30, 2026 · filed August 14, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Dianthus Therapeutics Inc | Trimmed | −2,104,184 | −$205M | 32.8% |
| Oruka Therapeutics Inc | Trimmed | −760,424 | −$72.4M | 11.6% |
| Jade Biosciences Inc | Trimmed | −1,100,708 | −$24.5M | 6.1% |
| Perspective Therapeutics Inc | Trimmed | −5,799,999 | −$19.8M | 3.4% |
| TP Teva Pharmaceutical Inds Ltd | Trimmed | −450,100 | −$15.2M | 1.1% |
| Aktis Oncology Inc | Trimmed | −452,932 | −$14.6M | 2.5% |
| Immunic Inc | Exited | −7,369,352 | −$13.9M | — |
| Enliven Therapeutics Inc | Trimmed | −250,000 | −$12.7M | 4.5% |
| Vir Biotechnology Inc | Trimmed | −1,050,000 | −$10.7M | 0.8% |
| PT Palvella Therapeutics Inc Ne | Trimmed | −70,000 | −$10.7M | 1.7% |
Showing the 10 largest of 56 changes.
quarter ended March 31, 2026 · filed May 28, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Dianthus Therapeutics Inc | Added | +2,104,184 | +$181M | 38.6% |
| Oruka Therapeutics Inc | Added | +860,424 | +$50.5M | 9.5% |
| Perspective Therapeutics Inc | Added | +8,889,265 | +$35.9M | 5.2% |
| Jade Biosciences Inc | Added | +1,400,708 | +$26.9M | 5.8% |
| Enliven Therapeutics Inc | Added | +659,700 | +$26.5M | 3.4% |
| Aktis Oncology Inc | New | +937,132 | +$17.2M | 1.8% |
| PT Palvella Therapeutics Inc Ne | Added | +120,700 | +$15.3M | 1.9% |
| Vir Biotechnology Inc | New | +1,569,300 | +$14.8M | 1.6% |
| Cg Oncology Inc | Trimmed | −183,751 | −$12.4M | 9.3% |
| Repligen Corp | Added | +105,300 | +$12.4M | 2.0% |
Showing the 10 largest of 67 changes.
quarter ended December 31, 2025 · filed February 13, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Dianthus Therapeutics Inc | Trimmed | −1,100,000 | −$45.3M | 25.0% |
| Natera Inc | Trimmed | −58,600 | −$13.4M | 0.8% |
| Bristol-myers Squibb Co | Exited | −257,600 | −$11.6M | — |
| Danaher Corporation | Trimmed | −37,700 | −$8.63M | 1.1% |
| Alnylam Pharmaceuticals Inc | New | +21,000 | +$8.35M | 2.4% |
| Medtronic PLC | Trimmed | −83,000 | −$7.97M | 3.0% |
| Metsera Inc | Exited | −140,500 | −$7.35M | — |
| Thermo Fisher Scientific Inc | Trimmed | −12,200 | −$7.07M | 1.1% |
| Unitedhealth Group Inc | Exited | −17,800 | −$6.15M | — |
| Icon PLC | New | +33,100 | +$6.03M | 1.7% |
Showing the 10 largest of 50 changes.
quarter ended September 30, 2025 · filed November 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Dianthus Therapeutics Inc | Added | +1,461,282 | +$57.5M | 28.7% |
| Natera Inc | Trimmed | −128,900 | −$20.7M | 2.6% |
| Tenet Healthcare Corp | Exited | −106,000 | −$18.7M | — |
| Dexcom Inc | Exited | −210,500 | −$18.4M | — |
| Medtronic PLC | New | +190,600 | +$18.2M | 4.1% |
| Hinge Health Inc | Exited | −322,344 | −$16.7M | — |
| Exact Sciences Corp | Trimmed | −281,400 | −$15.4M | 0.9% |
| Boston Scientific Corp | Trimmed | −157,500 | −$15.4M | 3.7% |
| IS Intuitive Surgival Inc | Exited | −27,100 | −$14.7M | — |
| Genmab A/s | Trimmed | −401,900 | −$12.3M | 1.7% |
Showing the 10 largest of 67 changes.
quarter ended June 30, 2025 · filed August 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Humana Inc | Exited | −80,000 | −$21.2M | — |
| Hinge Health Inc | New | +322,344 | +$16.7M | 3.3% |
| Regeneron Pharmaceuticals | Exited | −25,400 | −$16.1M | — |
| IS Intuitive Surgival Inc | New | +27,100 | +$14.7M | 2.9% |
| Natera Inc | Added | +80,100 | +$13.5M | 6.7% |
| Cg Oncology Inc | Added | +519,000 | +$13.5M | 7.8% |
| Genmab A/s | New | +650,000 | +$13.4M | 2.7% |
| Repligen Corp | New | +106,500 | +$13.2M | 2.6% |
| Glaukos Corp | Exited | −134,000 | −$13.2M | — |
| Humana Inc | Trimmed | −53,400 | −$13.1M | 1.3% |
Showing the 10 largest of 77 changes.
quarter ended March 31, 2025 · filed May 15, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Intuitive Surgical Inc | Exited | −64,800 | −$33.8M | — |
| Mirum Pharmaceuticals Inc | Trimmed | −626,200 | −$28.2M | 0.3% |
| AH Acadia Healthcare Company In | Exited | −658,000 | −$26.1M | — |
| Humana Inc | New | +80,000 | +$21.2M | 4.0% |
| Dianthus Therapeutics Inc | Trimmed | −1,152,098 | −$20.9M | 5.9% |
| Kymera Therapeutics Inc | Exited | −500,000 | −$20.1M | — |
| Jazz Pharmaceuticals PLC | Trimmed | −154,500 | −$19.2M | 1.9% |
| Boston Scientific Corp | Trimmed | −179,000 | −$18.1M | 6.5% |
| Neurocrine Biosciences Inc | Trimmed | −134,700 | −$14.9M | 1.8% |
| Natera Inc | Trimmed | −104,600 | −$14.8M | 3.2% |
Showing the 10 largest of 82 changes.
quarter ended December 31, 2024 · filed February 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Natera Inc | Trimmed | −332,600 | −$52.7M | 3.5% |
| Intuitive Surgical Inc | Trimmed | −83,400 | −$43.5M | 3.3% |
| Boston Scientific Corp | Trimmed | −447,000 | −$39.9M | 4.5% |
| Neurocrine Biosciences Inc | Trimmed | −239,600 | −$32.7M | 3.0% |
| Glaukos Corp | Trimmed | −174,900 | −$26.2M | 2.5% |
| Insmed Inc | Trimmed | −359,200 | −$24.8M | 1.6% |
| Illumina Inc | Trimmed | −182,300 | −$24.4M | 1.4% |
| Jazz Pharmaceuticals PLC | Trimmed | −196,500 | −$24.2M | 2.8% |
| Neumora Therapeutics Inc. | Exited | −1,800,000 | −$23.8M | — |
| Biomarin Pharmaceutical Inc | Exited | −320,000 | −$22.5M | — |
Showing the 10 largest of 86 changes.
quarter ended September 30, 2024 · filed November 14, 2024
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| The Cigna Group | Exited | −184,500 | −$61M | — |
| Alnylam Pharmaceuticals Inc | Exited | −222,000 | −$53.9M | — |
| Unitedhealth Group Inc | New | +87,400 | +$51.1M | 2.6% |
| Regeneron Pharmaceuticals | Exited | −48,000 | −$50.4M | — |
| Avantor Inc | Trimmed | −1,851,000 | −$47.9M | 1.6% |
| Intuitive Surgical Inc | Trimmed | −96,800 | −$47.6M | 3.7% |
| Humana Inc | New | +129,700 | +$41.1M | 2.1% |
| Merck & Co Inc | Exited | −325,000 | −$40.2M | — |
| Arvinas Inc | Trimmed | −1,490,845 | −$36.7M | 1.9% |
| Abbvie Inc | Trimmed | −177,800 | −$35.1M | 1.0% |
Showing the 10 largest of 94 changes.
Loading...
